Expert Clinical Framework Report: Management of Adverse Events Related to Novel Therapies for Relapsed Refractory Multiple Myeloma (RRMM). Can Hematol Today 2022, 1 (S11). https://doi.org/10.58931/cht.2022.1S1130.